SCHEMBL4494471

SCHEMBL4494471

O=C(O)C1CCCN(C(=O)c2ccncn2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G1B P04054 1/20 0.47
ATG4B Q9Y4P1 1/20 0.47
RECQL P46063 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
GRM3 Q14832 1/20 0.45
CNR2 P34972 1/20 0.44
MAPK1 P28482 1/20 0.44
KDM5A P29375 1/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 3/20 0.42
TP53BP1 Q12888 2/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
BLM P54132 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
SCD O00767 1/20 0.41
SCD5 Q86SK9 1/20 0.41
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4485391 0.83 PLA2G1B (0.65) PLA2G1BATG4BMEN1KMT2AALDH1A1
SCHEMBL4485387 0.83 PLA2G1B (0.65) PLA2G1BATG4BMEN1KMT2AALDH1A1
SCHEMBL21928885 0.82 MEN1 (0.51) PLA2G1BATG4BRECQLMEN1KMT2A
SCHEMBL4491936 0.80 KDM4E (0.58) PLA2G1BATG4BMEN1KMT2AKDM4E
SCHEMBL4491941 0.80 KDM4E (0.58) PLA2G1BATG4BMEN1KMT2AKDM4E
SCHEMBL4491933 0.80 KDM4E (0.58) PLA2G1BATG4BMEN1KMT2AKDM4E
SCHEMBL16615297 0.80 L3MBTL1 (0.51) MEN1KMT2ACNR2ALDH1A1NPC1
SCHEMBL28448703 0.74 L3MBTL1 (0.62) PLA2G1BATG4BMEN1KMT2AKDM4E
SCHEMBL7302157 0.74 ALDH1A1 (0.62) MEN1KMT2AGRM3KDM4EALDH1A1
SCHEMBL17546311 0.73 ACHE (0.50) RECQLKDM5AALDH1A1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598392-B2 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2009-10-06 US claimed
US-20070259847-A1 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2007-11-08 US claimed
US-7598392-B2 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2009-10-06 US disclosed
US-20070259847-A1 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259847-A1 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof PKD2, TPMT, PKD1 PLA2G1B 1160/4885ATG4B 873/4885RECQL 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.